- WKN: A1K022
- ISIN: DE000A1K0227
- Land: Deutschland
Nachricht vom 12.11.2019 | 11:34
CO.DON AG: CO.DON AG completes capital increase
DGAP-News: CO.DON AG
/ Key word(s): Capital Increase
CO.DON AG completes capital increase
Berlin / Teltow, 12 November 2019 - CO.DON AG (DE000A1K0227), one of the technology leaders in the production of human cell and tissue transplants, yesterday placed its cash capital increase with subscription rights from authorized capital resolved on October 21, 2019 by issuing 2,549,839 new shares. The gross proceeds will amount to approximately EUR 5.9 million.
Accordingly, the Company's share capital will be increased by EUR 2,549,839.00 from currently EUR 21,745,817.00 to EUR 24,295,656.00 by issuing 2,549,839 new bearer shares with a notional value of EUR 1.00 per share after entry in the commercial register.
The New Shares are to be admitted to trading on the regulated market (General Standard) of the Frankfurt Stock Exchange. The admission of the new shares to the existing listing of the Company (ISIN DE000A1K0227) is expected to take place around November 15, 2019.
In connection with the capital increase, the Company concluded a loan agreement with the major shareholder Bauerfeind Beteiligungsgesellschaft mbH in the amount of up to approx. EUR 1.6 million in order to substantiate earlier agreements with the shareholder. The funds from this loan are accessible until November 2020 and, alongside the funds generated from the capital increase, are intended to secure the liquidity required over the next twelve months.
Ralf M. Jakobs, CEO: "I would like to thank our loyal shareholders for their participation in the capital increase and their confidence in the company. By implementing this measure, we were able to strengthen our equity base, but at the same time we will evaluate further financing measures in due time to cover our liquidity requirements in order to pursue our strategy".
CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,500 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs (Spokesman), Tilmann Bur (COO).
Further information is available from www.codon.de.
Investor Relations and Press Contact
This publication does not constitute or form part of and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer and the prospectus approved by BaFin. This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as defined in Regulation S of the Securities Act), except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws, and should not be distributed to "U.S. persons" or by way of publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||910495|
|End of News||DGAP News Service|
Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet
Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.
Der AKTIONÄR News
25. September 10:35 Fraport: Flughafen-Verband warnt vor Insolvenz
25. September 09:58 Lufthansa: Neues 17-Jahres-Tief - brechen jetzt alle Dämme?
25. September 09:55 Chart-Check Puma: Ausbruch geglückt – neue Trading-Chance
25. September 09:50 Datenbank-Aktien: Von Schneeflöckchen und Börsenlawinen
25. September 09:43 AKTIONÄR Top-Tipp SAF-Holland: Neues Kursziel – Analyst sieht 130% ...
Original-Research: amalphi AG (von Sphene Capital GmbH): Buy
25. September 2020